With this Oral Cephalosporin approval, Aurobindo’s product basket for the US market has increased to 13 (Final approvals). Apart from this, the Company has 10 Tentative Approvals for the US market.

The size of generics business of Cefuroxime Axetil 125/250/500 mg is around USD 50 Mn.

Cefuroxime Axetil tablets are indicated for the treatment of patients with infections caused by susceptible strains of designated organisms in the following diseases: Pharyngitis and Tonsillitis, Lower Respiratory Tract Infections, Urinary Tract Infections and Skin Structure Infections.

Cefuroxime Axetil Tablets USP, 125 mg (base), 250 mg (base), 500 mg (base) is the generic version of Glaxo Wellcome's Ceftin^®.

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing (Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) around 65 APIs in the non-antibiotics and 55 APIs in the antibiotic segment. The Company is marketing these products globally, in over 100 countries.